Intratumoural administration of coxsackievirus A21 [CVA-21] for the control of malignant melanoma.

Trial Profile

Intratumoural administration of coxsackievirus A21 [CVA-21] for the control of malignant melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Viralytics
  • Most Recent Events

    • 15 Dec 2009 Planned initiation date (Sep 2005) added as reported by Australian New Zealand Clinical Trials Registry record.
    • 29 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top